No significant difference was observed in median rCBV between EGFR-non-amplified and amplified gliomas either in the entire patient cohort (Figure 6d; 1.22 ± 0.70 vs. 1.50 ± 0.76, p = 0.071) or in treatment-naïve patients (p = 0.449). Here, EGFR is linked to central nervous system cancer.